Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition

First Page		Document Content
Date: 2012-12-23 16:51:41 Organofluorides Cell biology Cell signaling ALK inhibitor Tyrosine kinase Anaplastic lymphoma kinase Platelet-derived growth factor receptor Anaplastic large-cell lymphoma Mitogen-activated protein kinase Biology Signal transduction Protein kinases		Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition Add to Reading List Source URL: www.brimr.org Download Document from Source Website File Size: 1,78 MB Share Document on Facebook

	Assessment RunCD30 Material The slide to be stained for CD30 comprised: 1-2. Tonsil, 3. Anaplastic large cell lymphoma (ALCL), 4. Embryonal carcinoma, DocID: 1v5rE - View Document
	Assessment RunLung Anaplastic Lymphoma Kinase (lu-ALK) Material The slide to be stained for lu-ALK comprised: 1. Appendix, 2. Tonsil, 3. Merkel cell carcinoma, 4. Anaplastic large cell lymphoma DocID: 1tVgY - View Document
	2nd Meeting of the European Research Initiative on ALCL June 27 th – 28 th 2011 Vienna, Austria DocID: 1o28e - View Document
	th 6 Meeting of the European Research Initiative on ALK-related Malignancies DocID: 1nHxo - View Document
	PDF Document DocID: 1npVD - View Document